[i] β-cit binding and spet compared with clinical diagnosis in parkinsonism

Nuclear Medicine Communications

Volumn 21, Issue 5, 2000, Pages 417-424

  Staffen, W ^a   Mair, A ^a   Unterrainer, J ^a   Trinka, E ^a   Bsteh, C ^a   Ladurner, G ^a  

^a Salzburger Landeskliniken   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

3BETA (4 IODOPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; COCAINE; DRUG DERIVATIVE; RADIOACTIVE IODINE;

ADULT; AGED; ARTICLE; BINDING SITE; CLINICAL TRIAL; HOSPITALIZATION; HUMAN; METABOLISM; METHODOLOGY; MIDDLE AGED; PARKINSONISM; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ADULT; AGED; AGED, 80 AND OVER; BINDING SITES; COCAINE; HUMANS; IODINE RADIOISOTOPES; MIDDLE AGED; PARKINSONIAN DISORDERS; SEVERITY OF ILLNESS INDEX; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0034180565     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200005000-00002     Document Type: Article

References (65)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely and Jones, 1817.
2. Rajput AH, Offord KP, Beard CM et al. Epidemiology of parkinsonism: Incidence, classification, and mortality. Ann Neurol 1984; 16: 278-282.
3. Spatz H. Physiologie und Pathologie des Hirnstammes. Handbuch der normalen und pathologischen Physiologie 1927; 10: 318.
4. Leenders KL. Pathophysiology of movement disorders studied using PET. J Neural Transm 1997; 50: 39-46.
5. Bernheimer H, Birkmayer W, Hornykiewicz O et al. Brain dopamine and the syndromes of Parkinson and Huntington. J Neurol Sci 1973; 20: 415-455.
6. Hornykiewicz O. Parkinson's disease and its chemotherapy. Biochem Pharmacol 1975; 24: 1061-1065.
7. Koller WC. How accurately can Parkinson's disease be diagnosed. Neurology 1992; 42: 6-16.
8. Riederer P, Wuketich S. Time course of nigrostriatal degeneration in Parkinson's disease: A detailed study of influential factors in human brain amine analogues. J Neural Transm Park Dis Dement Sect 1976; 38: 277-301.
9. Quinn N. Multiple system atrophy - the nature of the beast. J Neurol Neurosurg Psychiat 1989; (spec. suppl.): 78-89.
10. Allard P, Alafuzoff J, Carlsson A et al. Loss of dopamine uptake sites labelled with [3H]-GBR-12935 in Alzheimer's disease. Eur Neurol 1990; 30: 181-185.
11. 125I]-RTI-55: A patent ligand for dopamine transporters. Eur J Pharmacol 1991; 194: 133-134.
12. 123I] β-CIT: Binding kinetics in the human brain. J Neural Transm 1993; 94: 137-146.
13. 123I] β-CIT binding to dopamine transporters in healthy human subjects. J Cereb Blood Flow Metab 1994; 14: 982-994.
14. 123I]-2β-carboxymethoxy-3β-(4iodophenyl)-tropane β-CIT: High affinity SPECT radiotracer of monoamine re-uptake sites in brain. J Med Chem 1991; 34: 3144-3146.
15. Niznik HB, Fogel EF, Fasso FF et al. The dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleus. J Neurochem 1991; 56: 192-198.
16. Perry EK, Marshall EF, Blessed G et al. Decreased imipramine binding in the brain of patients with depressive illness. Br J Psychiat 1983; 142: 188-192.
17. 2 dopamine receptors in SPECT. Life Sci 1988; 42: 2097-2104.
18. Garnett ES, Finnan G, Nahmias G. Dopamine visualized in the basal ganglion of living man. Nature 1983; 305: 137-138.
19. 2 receptor imaging radiopharmaceuticals: Synthesis, radiolabelling, and in vitro binding of (R)-(+)- and (S)-(−)-3iodo-2hydroxy-6methoxy-N-[1ethyl-2pyrrolidinyl-methyl]benzamide. J Med Chem 1988; 31: 1039-1043.
20. 123-IBZM in humans. J Nucl Med 1991; 31: 573-579.
21. 125I]-IBZM and its biodistribution and kinetic properties. Kagu Igaku 1994; 31: 513-519.
22. 123-IBZM. J Nucl Med 1992; 33: 1964-1971.
23. 123I-IBZM in humans. Ann Nucl Med 1993; 7: 29-38.
24. 2 dopamine receptor density using equilibrium analysis. Kagu Igaku 1994; 31: 1117-1120.
25. 2 receptor and technetium-99m HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's disease. J Nucl Med 1993; 34: 1274-1281.
26. Innis RB, Seibyl JP, Wallace E et al. SPECT imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. J Nucl Med 1993; 34: 31.
27. 123I] β-CIT. Eur J Pharmacol 1991; 299: 369-370.
28. 123I] β-CIT: Pharmacological characterization of brain uptake in nonhuman primates. Synapse 1993; 13: 295-309.
29. 125I] RTI-55, an in vivo label for the serotonin transporter. Synapse 1992; 11: 134-139.
30. Shaya EK, Scheffel U, Dannals RF et al. In vivo imaging of dopamine uptake sites in primate brain using single photon emission tomography (SPECT) and iodine-123 labelled RTI-55. Synapse 1992; 10: 169-172.
31. 11C] beta CIT binding to monoamine transporters in the monkey and human brain. Synapse 1994; 16: 93-103.
32. 125I] RTI-55: In vitro binding and autoradiographic characterization. J Neurochem 1994; 62: 549-556.
33. 3H] GBR-12935 binding to the dopamine transporter is decreased in the caudate nucleus in Parkinson's disease. J Neurochem 1987; 49: 617-621.
34. Maloteaux JM, Vanisberg MA, Laterre C et al. Hydrogen-3-GBR-12935 binding to dopamine uptake sites: Subcellular localization and reduction in Parkinson's disease and progressive supranuclear palsy. Eur J Pharmacol 1988; 156: 331-340.
35. 3H] cocaine binding to the dopamine transporter in Parkinson's disease. Eur J Pharmacol 1983; 95: 145-146.
36. 123I] β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997; 38: 1-5.
37. 123I] β-CIT and SPECT correlates with clinical findings. Move Disord 1994; 9(suppl. 1): 120.
38. 123I] β-CIT and SPECT. J Cereb Blood Flow Metab 1995; 15(suppl. 1): 37.
39. 123I] β-CIT and SPECT. J Neural Transm 1997; 50: 9-24.
40. Kuikka JT, Bergström KA, Vanninen E et al. Initial experience with single photon emission tomography using iodine-123-labelled 2β-carbomethoxy-3β-(4-iodophenyl)tropane in human brain. Eur J Nucl Med 1993; 20: 783-786.
41. Marek KL, Seibyl JP, Sandridge B et al. SPECT imaging demonstrates striatal dopamine transporter loss in hemiparkinsonism. Soc Neurosci Abstr 1994; 20: 1780.
42. 123I] β-CIT SPECT. Parkinsonism Related Disord 1995; 1: 47-51.
43. 123I] β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
44. Staffen W, Hondl N, Trinka E et al. SPET investigations in extrapyramidal diseases using specific ligands. Nucl Med Commun 1997; 18: 159-163.
45. 123I] β-CIT binding with SPECT in controls, early and late Parkinson's disease. Nucl Med Biol 1995; 22: 985-991.
46. Hughes AJ, Daniel SE, Kilford L et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiat 1992; 55: 181-184.
47. Hoehn MM, Yahr MD. Parkinsonism: Onset, progression and mortality. Neurology 1967; 17: 427-442.
48. McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB). Neurology 1996; 47: 1113-1124.
49. Quinn N. Multiple system atrophy. In: Marsden CD, Fahn S, eds. Movement disorders 3. London: Butterworth-Heinemann, 1994: 262-281.
50. 3H] paroxetine binding, a marker of serotonin uptake sites. Biol Psychiat 1988; 24: 299-309.
51. 123I]-N-Isopropyl-Amphetamin. Nuc Compact 1984; 15: 305-314.
52. Podreka I, Baumgartner C, Suess E et al. Quantification of regional cerebral blood flow with IMP-SPECT: Reproducibility and clinical relevance of flow values. Stroke 1989; 20: 183-191.
53. 2 receptor binding in the living human brain by PET. Science 1986; 231: 258-261.
54. Hatazawa J. The effect of neuroleptics on human brain estimated by SPECT and PET. Kaku Igaku 1993; 30: 687-692.
55. Leenders KL, Salmon ED, Tyrrell P et al. The nigrostriatal dopaminergic system assessed in vitro by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47: 1290-1298.
56. 11C-raclopride PET findings in patients with parkinsonism. Nucl Med Commun 1994; 15: 806-813.
57. Giros B, Mestikawy SE, Bertrand L et al. Cloning and functional characterization of a cocaine-sensitive dopamine transporter. FEBS Lett 1991; 295: 149-154.
58. Kilty JE, Lorang D, Amara SG. Cloning and expression of a cocaine-sensitive rat dopamine transporter. Science 1991; 254: 578-579.
59. Lorang D, Amara SG, Simerly RB. Cell-type-specific expression of catecholamine transporters in the rat brain. J Neurosci 1994; 14: 4903-4914.
60. 123I] β-CIT-SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
61. 18F-Dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Ann Neurol 1990; 28: 547-555.
62. German DC, Manaye K, Smith WK et al. Midbrain dopaminergic cell loss in Parkinson's disease: Computer visualization. Ann Neurol 1989; 26: 507-514.
63. Goto S, Hirano A, Matsumoto S. Subdivisional involvement of nigrostriatal loop in idiopathic Parkinson's disease and striatonigral degeneration. Ann Neurol 1989; 26: 766-770.
64. Jellinger K, Riederer P, Tomanaga M. Progressive supranuclear palsy: Clinico-pathological and biochemical studies. J Neural Transm 1980; 16: 111-128.
65. Tissingh G, Booij J, Winogrodzka A et al. IBZM- and CIT-SPECT of the dopaminergic system in parkinsonism. J Neural Transm 1997; 50(suppl.): 31-37.